Kamada (KMDA) Stock Price, News & Analysis

Company Overview

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Key Stats

• Today's Range: $7.77 to $7.88
• 50-Day Range: $6.47 to $7.95
• 52-Week Range: $5.08 to $9.16
• Volume: 23,331 shs
• Average Volume: 96,622 shs
• Market Capitalization: $446.05 million
• P/E Ratio: 26.74
• Dividend Yield: N/A
• Price Target: $13.00
• Consensus Rating: Moderate Buy

Kamada Stock Analysis - MarketRank™

Kamada scored higher than 83% of companies evaluated by MarketBeat, and ranked 514th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Kamada has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Kamada has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.8 / 5
• Proj. Earnings Growth: 39.13%

Earnings Growth

Earnings for Kamada are expected to grow by 39.13% in the coming year, from $0.23 to $0.32 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Kamada is 26.74, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.53.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kamada is 26.74, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.38.

Price to Earnings Growth Ratio

Kamada has a PEG Ratio of 0.94. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Kamada has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.42% of the float of Kamada has been sold short.

Short Interest Ratio / Days to Cover

Kamada has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kamada has recently increased by 168.66%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kamada does not currently pay a dividend.

Dividend Growth

Kamada does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.42% of the float of Kamada has been sold short.

Short Interest Ratio / Days to Cover

Kamada has a short interest ratio ("days to cover") of 1.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kamada has recently increased by 168.66%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: N/A

News Sentiment

Kamada has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Kamada this week, compared to 2 articles on an average week.

Search Interest

8 people have searched for KMDA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

5 people have added Kamada to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kamada insiders have not sold or bought any company stock.

Percentage Held by Insiders

36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 20.38% of the stock of Kamada is held by institutions.

KMDA Stock Analysis - Frequently Asked Questions

How have KMDA shares performed this year?

Kamada's stock was trading at $6.09 at the beginning of the year. Since then, KMDA stock has increased by 27.4% and is now trading at $7.7560.

How were Kamada's earnings last quarter?

Kamada Ltd. (NASDAQ:KMDA) released its quarterly earnings results on Wednesday, May, 14th. The biotechnology company reported $0.07 EPS for the quarter, hitting analysts' consensus estimates of $0.07. The biotechnology company earned $44.02 million during the quarter, compared to analysts' expectations of $154.06 million. Kamada had a trailing twelve-month return on equity of 6.31% and a net margin of 9.60%.
Read the conference call transcript.

How do I buy shares of Kamada?

Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Kamada own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Kamada investors own include Xtrackers California Municipal Bond ETF (CA), BlackRock (BLK), Endologix (ELGX), NVIDIA (NVDA), Chipotle Mexican Grill (CMG), ASML (ASML) and Oracle (ORCL).

Company Calendar

• Record date for 4/7 Dividend: 3/17/2025
• Ex-Dividend for 4/7 Dividend: 3/17/2025
• Dividend Payable: 4/07/2025
• Last Earnings: 5/14/2025
• Today: 7/03/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:KMDA
• CIK: 1567529
• Web: www.kamada.com
• Phone: (728) 940-6472
• Fax: 972-8940-6473
• Employees: 360
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $13.00
• High Stock Price Target: $15.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +67.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.29
• Trailing P/E Ratio: 26.74
• Forward P/E Ratio: 33.72
• P/E Growth: 0.94
• Net Income: $14.46 million
• Net Margins: 9.60%
• Pretax Margin: 10.47%
• Return on Equity: 6.31%
• Return on Assets: 4.43%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.30
• Quick Ratio: 1.93

Sales & Book Value

• Annual Sales: $160.95 million
• Price / Sales: 2.77
• Cash Flow: $0.49 per share
• Price / Cash Flow: 15.78
• Book Value: $4.51 per share
• Price / Book: 1.72

Miscellaneous

• Outstanding Shares: 57,510,000
• Free Float: 36,746,000
• Market Cap: $446.05 million
• Optionable: Optionable
• Beta: 0.96